A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer

Summary

This is the first study of MLN2704 administered to humans. The purpose of the study is to determine the highest dose of MLN2704 that can be given safely to patients with prostate cancer, and to identify any side effects associated with taking the drug. This study will also evaluate how MLN2704 is taken up (absorbed), broken down (metabolized) and eliminated (excreted) by the body. This process is called pharmacokinetic analysis.

Timeline

Start

2002-11

Primary completion

—

Completion

—

Drugs

Indications